Search

Two UT Southwestern Medical Center scientists – Zhijian “James” Chen, Ph.D., Professor of Molecular Biology and Director of the Center for Inflammation Research, and Michael Rosen, Ph.D., Chair and Professor of Biophysics – have been selected as 2025 Citation Laureates in recognition of work deemed

Zhijian “James” Chen, Ph.D., Professor of Molecular Biology and Director of the Center for Inflammation Research at UT Southwestern Medical Center, has been elected to the Fellowship of the Royal Society, the United Kingdom’s national academy of sciences and the oldest scientific academy in

Most days, neurologist Sasha Alick-Lindstrom, M.D., M.P.H., FAAN, FACNS, FAES, can be found staring at rows of brain signals on multiple computer screens, inspecting the squiggly lines for any irregularities or spikes of electrical activity.

Samuel Achilefu, Ph.D., inaugural Chair of Biomedical Engineering at UT Southwestern Medical Center and an internationally recognized leader in the fields of molecular imaging of cancer and nanotherapeutics, has been elected to the National Academy of Engineering (NAE).

A new robotic surgery device allows for all of the necessary surgical tools to be inserted through one 1-inch hole, whereas standard laparoscopic surgery requires five or six small incisions.

Scientists have developed a method to boost the efficiency of CRISPR gene editing in Duchenne muscular dystrophy (DMD), according to a study that could have implications for optimizing gene therapies for other diseases.

UT Southwestern researchers have identified two proteins that act as gatekeepers to dampen a potentially life-threatening immune response to chronic infection.

 UT Southwestern is the only clinical trial site in the U.S. using a new form of brain stimulation to treat major depression.

UT Southwestern Medical Center scientists for the first time have calculated and mapped life expectancy by gender and race/ethnicity down to the ZIP code and county levels in Texas.

Elevated calcium levels in the blood – a complication of kidney cancers known as hypercalcemia – may be successfully treated with a class of medications called HIF-2 inhibitors developed by UT Southwestern Medical Center, a new study shows. The findings, published in Cancer Discovery by a team at